title: Increased serum levels of neuron-specific enolase in epileptic patients and after electroconvulsive therapy--a preliminary report.
abstract: Serum neuron-specific enolase (NSE) levels were studied by an enzymo-immunoassay method in 2 groups of patients: a group of epileptic patients, and a group of patients with refractory major depression after electroconvulsive therapy (ECT). In patients without organic neurological disease (n = 274) the mean serum NSE level (+/- S.D.) was 8.4 +/- 3.4 micrograms/l. No correlation with sex or age was observed. No significant difference was observed between epileptic patients without seizure or major electroencephalogram (EEG) abnormality, and a reference group. Significant increases were observed in 32 samples collected from patients with interictal EEG without spikes and waves before the 7th day after a seizure, in whom mean NSE was 21.5 +/- 9.4 micrograms/l, and in 26 samples from 4 patients without seizures but with spikes and waves in the interictal EEG, whose mean NSE was 20.6 +/- 11.5 micrograms/l. The increases of serum NSE levels in epileptic patients seem therefore to be linked to seizures and/or to EEG abnormalities. The consequences of these observations for the survey of epileptic patients, and for the diagnosis of cerebral tumors (mainly neuroblastoma) or for monitoring treatment after surgical resection, are discussed. In only 1 patient out of 6, an increase in serum NSE levels was observed with a peak about 12 h after ECT. No significant correlation with the ECT features (length of seizures, one- or two-sided electrodes) was observed.
authors.affiliation: Service de Biologie Générale et de Neurobiologie, Centre Hospitalier Spécialisé du Vinatier, Bron-Lyon, France.
authors.forename: J
authors.initials: J
authors.lastname: Greffe
authors.forename: P
authors.initials: P
authors.lastname: Lemoine
authors.forename: C
authors.initials: C
authors.lastname: Lacroix
authors.forename: A M
authors.initials: AM
authors.lastname: Brunon
authors.forename: J L
authors.initials: JL
authors.lastname: Terra
authors.forename: J
authors.initials: J
authors.lastname: Dalery
authors.forename: E
authors.initials: E
authors.lastname: Bernier
authors.forename: I
authors.initials: I
authors.lastname: Soares-Boucaud
authors.forename: T
authors.initials: T
authors.lastname: Rochet
authors.forename: T A
authors.initials: TA
authors.lastname: Leduc
authors.forename: G
authors.initials: G
authors.lastname: Balvay
authors.forename: P
authors.initials: P
authors.lastname: Mathieu
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000927:Anticonvulsants / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D004565:Electroconvulsive Therapy; D004569:Electroencephalography; D004827:Epilepsy / Q000097:blood* / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010751:Phosphopyruvate Hydratase / Q000097:blood*; D012016:Reference Values; D013997:Time Factors
chemical_list: D000927:Anticonvulsants; D015415:Biomarkers; D010751:Phosphopyruvate Hydratase